The need to overcome drug-resistant mutations in viruses (7, 8, 14, 20, 22) and adverse effects during long-term human immunodeficiency (HIV) and hepatitis B virus (HBV) therapies have led to the development of several novel antiviral nucleoside agents (1, 2, 4, 6, 9, 11, 17, 21, 23, 24, 27, 28) . Pharmacokinetic studies with relevant animal models are critical to determine important pharmacokinetic parameters that are needed to develop rational starting dose regimens for clinical trials in humans.
␤-L-3Ј-Fluoro-2Ј,3Ј-didehydro-2Ј,3Ј-dideoxycytidine (L-3Ј-Fd4C) is a potent inhibitor of viral replication in the chronically HBVinfected HepAD79 cell line (90% effective concentration [EC 90 ] of Ͻ3.1 M) containing the rtM204V mutation and against wild-type HIV type 1 (HIV-1)-infected human peripheral blood mononuclear cells (EC 90 of Ͻ0.22 M) (5, 6, 13, 30) . The D-analogues in the series of nucleosides related to L-3Ј-Fd4C were mostly inactive against HIV-1 (EC 90 of Ͼ10 M). However, it has been previously demonstrated that nucleosides containing modifications at the 2Ј and 3Ј positions of the sugar moiety can have potent activity against resistant mutant viruses (4, 5, 13, 15, 30) . L-3Ј-Fd4C was essentially nontoxic to various cells and had no mitochondrial toxicity in HepG2 cells at concentrations up to 100 M; it was nontoxic to mice when administered intraperitoneally in a dosage of 100 mg/kg of body weight for 6 days.
The objective of this study was to determine the single dose pharmacokinetics of L-3Ј-Fd4C in rhesus monkeys following intravenous ([i.v.] in sterile saline) and oral administration. The nucleoside was administered orally both with and without bicarbonate buffer for comparison, since D-D4FC (Reverset), developed earlier in our laboratory, is a 5-fluorine-containing cytidine analogue that is unstable at gastric pH. The bioavailability of D-D4FC in monkeys was improved when administered with sodium bicarbonate buffer (16) . However, L-3Ј-Fd4C is known to be stable for at least 1 h at neutral, low-acidic and high-alkaline conditions at room temperature (5, 25) . Nevertheless, we hypothesized that the use of bicarbonate may increase its oral bioavailability.
METHODS AND MATERIALS
Chemicals. The synthesis of L-3Ј-Fd4C (molecular weight, 227.19) (Fig. 1 ) and the internal standard 3TC (lamivudine) have been described else where (5, 13, 30) . The chemical purity of each compound was determined by high-performance liquid chromatographic (HPLC) and spectral analysis to be greater than 98%. Acetonitrile (HPLC grade) and all other chemicals (analytical grade) were obtained from Fisher Scientific (Fair Lawn, N.J.).
Pharmacokinetic studies in monkey. Three female rhesus monkeys (Macaca mulatta) weighing from 5.1 to 6.5 kg were used for the pharmacokinetic studies. The animals were housed at the Yerkes Regional Primate Research Center at Emory University, which is fully accredited by the American Association for Accreditation of Laboratory Animal Care, in accordance with guidelines established by the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals (18) of the National Institutes of Health. Monkeys were administered a single dose of 25 mg/kg of body weight of L-3Ј-Fd4C i.v. in 10 ml of sterile saline. After a washout period of at least 4 weeks, monkeys were given oral doses (p.o.) of 25 mg/kg of body weight of L-3Ј-Fd4C, administered by gastric intubation, in a total volume of 10 ml of water, followed by a further 3 ml of water. Saturated sodium bicarbonate (10 ml) was administered by nasogastric tube to each monkey for the bicarbonate oral administration (o.b.) prior to treatment with L-3Ј-Fd4C. Animals were maintained on their backs on a heating pad, covered with a blanket and under anesthesia for 4 h after dosing with a mixture of ketamine HCl (60 mg) and tiletamine HCl plus zolazepam HCl (Telazol; 20 mg) intramuscularly, and monitored for alertness. Additional anesthetics (30 to 60 mg of ketamine HCl) were administered as necessary. This method of anesthesia was used since it was considered less likely to cause a pharmacokinetic interaction than volatile anesthetics (31) . Blood samples were taken at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after drug administration through the femoral vein. Cerebrospinal fluid (CSF) samples were taken from all treated monkeys at 1 h after drug administration by cisternal or lumbar tap with a 22-gauge needle. The monkeys were catheterized for urine collection. Urine samples were collected at 0 to 0.25, 0.25 to 0.5, 0.5 to 1, 1 to 1.5, 1.5 to 2, 2 to 3, 3 to 4, 4 to 6, and 6 to 8 h after dosing. Plasma, CSF, and urine samples were kept on ice and then frozen at Ϫ70°C until used for analyses.
HPLC analysis of L-3-Fd4C in monkey plasma, urine, and CSF samples. HPLC analysis was performed by using a Hitachi HPLC system (Tokyo, Japan) equipped with a model L-7100 pump, a model L-7420 detector, and a model L-7250 autosampler with a Phenomenex Columbus C 18 reverse-phase column (4.6 by 250 mm; 5-m particle diameter). The mobile phase was isocratic 6% acetonitrile and 94% water. The flow rate was maintained at 0.7 ml/min. L-3Ј-Fd4C and the internal standard 3TC were detected at a wavelength of 270 nm and eluted from the column at 12.5 and 14 min, respectively. Preparation of standards. Standard solutions of L-3Ј-Fd4C were prepared in deionized water. Calibration plots for L-3Ј-Fd4C in plasma were prepared by adding standard solutions to the plasma of an untreated monkey at concentrations ranging from 0.1 to 100 g/ml. Standard curves for the analysis of urine and CSF samples were prepared by using urine and deionized water, respectively, over the same concentration range. The intraday accuracy and precision of the assay methodologies for plasma were determined by assaying six samples per concentration level on the same day. For interday assay accuracy and precision determinations, samples were analyzed on three separate days. Precision was reported as relative standard deviations, and accuracy was calculated by comparing measured concentrations to the known values. The intraday and interday relative standard deviations were less than 9%, and the intraday and interday accuracies were greater than 91%. The standard curves were linear over a concentration range of 0.1 to 100 g/ml (r 2 ϭ 0.999). Under these conditions, L-3Ј-Fd4C was baseline separated in monkey plasma, urine, and CSF samples. Extraction procedure. For plasma samples, 2.0 l of 3TC (0.5 mg/ml) was added as an internal standard to a 50-l plasma sample in a microcentrifuge tube. Acetonitrile (250 l) was added before vortexing and centrifuged at 7,800 ϫ g for 5 min. The supernatant was evaporated to dryness, and the samples were reconstituted with 100 l of 5% acetonitrile in water and injected onto the HPLC column. The HPLC method was validated according to the Food and Drug Administration's Guidelines for Industry Bioanalytic Method Validation protocol (26) . The extraction recovery of L-3Ј-Fd4C was calculated by comparing the mean peak area for six extracted plasma samples with that of the three standard samples containing the same amount of nucleoside. Low (0.5 g/ml), medium (5 g/ml), and high (50 g/ml) concentration levels were investigated. The percent extraction recovery was calculated as follows: 100 ϫ A extracted /A standard , where A extracted is the peak area of extracted drug from biological fluid and A standard is the peak area of same amount of drug without extraction. The extraction recovery of L-3Ј-Fd4C was greater than 89%.
For CSF samples, 2 l of internal standard (3TC; 0.5 g/ml) was added to 50 l of CSF samples and 48 l of water, and 50 l of sample was injected onto the HPLC column for analysis. Urine samples were diluted 20-to 50-fold, and 4 l of the same internal standard was added to 200 l of diluted urine, and the mixture was injected onto the HPLC for analysis.
Pharmacokinetic analysis. The areas under the concentration-time curve after oral dose (AUC oral ), maximum plasma concentration (C max ), time of maximum concentration (T max ), bioavailability, and apparent terminal phase half-life (t 1 12 and k 21 , first-order disposition rate constants between compartment 1 and compartment 2), which may otherwise be obscured by the oral absorption, and avoids reporting two sets of disposition rate constants for the same animal. However, this approach assumes that the intercompartment disposition rate constants remain consistent once the drug reaches the circulation (4, 10) . Initial estimates for model parameters were obtained by using parameters from similar compounds tested in rhesus monkeys (12) . A weighting factor of 1/(predicted value)
1.5 was used for fitting the plasma data (Fig. 2) . Since the accumulation of L-3Ј-Fd4C in the urine had not plateaued at 8 h, the fraction excreted in the urine and renal clearance (CL renal ) could not be calculated directly. The CL renal value was derived from a model fitted to the urine excretion data by using the pharmacokinetic parameters derived from the plasma data. The following equation was used: dX u /dt ϭ CL renal ϫ C p , where dX u is the rate of renal accumulation of compound during time interval dt, and C p is the predicted concentration of the drug in the plasma based on the plasma data coinciding with the urine collection interval (4) . No weighting factor was used for the urine data.
Other pharmacokinetic parameters listed in Table 1 were calculated by using standard two-compartment equations. For the area under the plasma concentration-time curve following i.v. dose (AUC iv ) and the AUC oral the equations were as follows: AUC iv ϭ dose/V ⅐ (␣ Ϫ k 21 )/(␣ Ϫ ␤)/␣ ϩ dose/V ⅐ (k 21 Ϫ ␤)/(␣ Ϫ ␤)/␤ and AUC oral ϭ F ⅐ AUC iv , where V is the distribution volume of the central compartments, ␣ and ␤ are biexponential elimination rate constants (more rapid and less rapid, respectively) from plasma, and F is the fraction of oral dose absorbed. Other calculations were made as follows: for the terminal phase half-life, t 1/2␤ ϭ ln (2)/␤; for systemic clearance, CL ϭ dose/AUC iv ; for the mean residence time after i.v. dosing,
; for the mean residence time after oral dosing, MRT oral ϭ MRT iv ϩ 1/K a , where K a is the absorption rate constant; for the steady-state distribution volume, V ss ϭ CL ⅐ MRT iv ; and for the mean absorption time, MAT ϭ 1/K a (10, 12) .
RESULTS
Pharmacokinetic studies. The paired t test of nontransformed and log-transformed data of the parameters C max , T max , AUC oral , bioavailability, and t 1/2 (8 to 24 h) obtained from noncompartmental analysis failed to detect significant differences in oral doses, in the presence and absence of bicarbonate (two-tailed P values of Ն0.45). Therefore, the twocompartment pharmacokinetic model was fitted for individual monkeys by using the i.v. and oral doses, without bicarbonate buffer data. The results are summarized in Table 1 , and the pooled fit is depicted in Fig. 2 .
The serum concentrations of L-3Ј-Fd4C at 24 h were below the limit of detection (LOD) for the i.v. doses but were above the LOD for the oral doses. The average percentages recov- 
DISCUSSION
L-3Ј-Fd4C is a nucleoside with potent and selective dual activity against HIV and HBV activities in vitro (5, 6, 30) . This nucleoside is structurally similar to L-(2,3-dideoxy-2-fluoro-␤-Lglyceropent-2-enofuranosyl)cytosine (L-2Ј-Fd4C) and D-D4FC (Reverset) (4, 16, 17) . However, D-D4FC has a fluorine moiety at the 5 position of the pyrimidine base, while L-2Ј-Fd4C and L-3Ј-Fd4C are fluorinated in the sugar ring (2Ј and 3Ј positions). Since D-D4FC is unstable at gastric pH and has improved bioavailability in bicarbonate buffer, we compared the oral bioavailability of L-3Ј-Fd4C with and without bicarbonate. However, we failed to determine significant differences in C max , T max , AUC 0-ϱ and t 1/2 (8 to 24 h) values (P Ն 0.05) using only three animals. Furthermore, the two-compartment open model described the single 25 mg/kg i.v. and oral doses of each animal (r Ͼ 0.92; Table 1 ), and the data of the pooled model appear to describe both oral formulations, even though the data from the bicarbonate formulation were not used for model fitting (Fig. 2) . Since the bioavailability (F %) of L-3Ј-Fd4C was not improved in the presence of sodium bicarbonate, other formulation or prodrug approaches should be considered to improve the oral absorption. The antiviral activity of L-3Ј-Fd4C against 3TC-resistant virus (EC 90 value of Ͻ3.1 M, or 0.7 g/ml) and against wildtype virus (EC 90 value of Ͻ0.22 M, or 0.05 g/ml) was previously reported (5, 6, 25, 30) . The concentration of L-3Ј-Fd4C in the plasma of rhesus monkeys remained higher than the EC 90 value against 3TC-resistant virus after 8 h for i.v. and 12 h for the oral doses and against wild-type HIV-1, 12 h after the i.v. and oral doses. The pharmacokinetic profile of L-3Ј-Fd4C suggests that this compound may have potential as an antiretroviral drug. Moreover, L-3Ј-Fd4C was found to be nontoxic in many cells and in the mitochondria of HepG2 cells at concentrations up to 100 M, and in mice given up to 100 mg/kg of body weight intraperitoneal doses for 6 days (5, 25, 30 ). Therefore, L-3Ј-Fd4C could be a useful candidate for individuals coinfected with HBV and HIV. R. F. Schinazi and C. K. Chu are founders of Pharmasset, Inc. This company has certain rights to the nucleosides described in this paper. Neither scientist received any funding from Pharmasset to conduct these studies.
